Inhibikase Therapeutics (IKT) Institutional Ownership $1.43 -0.12 (-7.74%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 08/8/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)23TotalInstitutional Inflows(last 12 months)$80.18MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$476.14K Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/8/2025 Intech Investment Management LLC31,406$61K0.0%N/A0.042% 8/8/2025 Police & Firemen s Retirement System of New Jersey17,638$34K0.0%N/A0.024% 8/8/2025 Geode Capital Management LLC1,066,700$2.08M0.0%+228.5%1.435% 6/27/2025Goldman Sachs Group Inc.166,025$364K0.0%+277.7%0.223% 5/19/2025Jane Street Group LLC116,249$255K0.0%N/A0.156% 5/16/2025Goldman Sachs Group Inc.166,025$364K0.0%+277.7%0.223% 5/16/2025ADAR1 Capital Management LLC5,122,105$11.22M2.1%+0.4%6.890% 5/14/2025Stonepine Capital Management LLC914,973$2.00M1.9%-19.2%1.231% 5/9/2025 Blair William & Co. IL155,953$342K0.0%+15.6%0.210% 5/6/2025 Y Intercept Hong Kong Ltd26,775$59K0.0%N/A0.036% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/27/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/18/2025Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/17/2025Soleus Capital Management L.P.6,325,000$20.56M1.3%N/A9.119% 2/17/2025Squarepoint Ops LLC28,411$92K0.0%N/A0.041% 2/17/2025Stonepine Capital Management LLC1,132,388$3.68M3.0%N/A1.633% 2/17/2025OMERS ADMINISTRATION Corp54,600$177K0.0%N/A0.079% 2/17/2025Millennium Management LLC142,209$462K0.0%N/A0.205% 2/17/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/17/2025Fairmount Funds Management LLC6,125,000$19.91M2.0%N/A8.831% 2/17/2025Blackstone Inc.2,070,684$6.73M0.0%N/A2.985% 2/17/2025Caxton Corp16,393$53K0.3%N/A0.024% 2/14/2025Nantahala Capital Management LLC2,190,000$7.12M0.3%N/A3.157% 2/14/2025Northern Trust Corp64,011$208K0.0%N/A0.092% 2/14/2025Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/14/2025Stifel Financial Corp13,129$43K0.0%N/A0.019% 2/13/2025Barclays PLC84,000$273K0.0%N/A0.121% 2/13/2025ADAR1 Capital Management LLC5,103,005$16.59M3.3%N/A7.357% 2/12/2025 Geode Capital Management LLC322,878$1.05M0.0%+544.9%0.466% 2/12/2025 Blair William & Co. IL134,953$439K0.0%+7.0%0.195% 8/15/2024Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% Buffett’s $325 Billion Cash Problem — Solved by Gold? (Ad)A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most investors are still asleep… but not for long. Garrett Goggin’s latest research reveals how you can “front-run” the greatest investor alive by positioning in four small miners sitting on up to 100X potential upside. When this hits the news — it’ll be too late.Discover how you could front-run Buffett’s gold move with Garrett’s Top Four picks.2/14/2022Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, 23 institutional investors and hedge funds held shares of Inhibikase Therapeutics. The most heavily invested institutionals were Soleus Capital Management L.P. ($20.56M), Fairmount Funds Management LLC ($19.91M), ADAR1 Capital Management LLC ($11.22M), Nantahala Capital Management LLC ($7.12M), Blackstone Inc. ($6.73M), Geode Capital Management LLC ($2.08M), and Stonepine Capital Management LLC ($2.00M).Learn more on Inhibikase Therapeutics' institutional investors. What percentage of Inhibikase Therapeutics' stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics' stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics' stock? Of the 23 institutional investors that purchased Inhibikase Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($6.33M), Fairmount Funds Management LLC ($6.13M), ADAR1 Capital Management LLC ($5.12M), Nantahala Capital Management LLC ($2.19M), Blackstone Inc. ($2.07M), Stonepine Capital Management LLC ($1.13M), and Geode Capital Management LLC ($1.01M). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 25,497,589 shares in the last 24 months. This purchase volume represents approximately $80.18M in transactions. Which of Inhibikase Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Stonepine Capital Management LLC ($217.42K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 217,415 shares in the last 24 months. This volume of shares sold represents approximately $476.14K in transactions. Related Companies SIGA Major Shareholders PRTC Major Shareholders GOSS Major Shareholders CGEM Major Shareholders SVRA Major Shareholders SNDL Major Shareholders MBX Major Shareholders ATYR Major Shareholders CMPS Major Shareholders KMDA Major Shareholders This page (NYSE:IKT) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts